Skip to main content
CRIS
NASDAQ Life Sciences

Stockholders Approve 100% Increase in Authorized Common Stock Amid Delisting Threat

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$0.501
Mkt Cap
$19.536M
52W Low
$0.464
52W High
$3.13
Market data snapshot near publication time

summarizeSummary

Curis Inc. stockholders approved a 100% increase in authorized common stock, enabling the company to issue up to 567.5 million shares. This move is crucial for the financially distressed company, which is facing delisting and has expressed 'going concern' doubts.


check_boxKey Events

  • Authorized Shares Doubled

    Stockholders approved an amendment to increase the authorized common stock from 283,757,150 to 567,514,300 shares, a 100% increase. This provides significant capacity for future capital raises.

  • Preferred Stock Designations Eliminated

    The company eliminated the designations for Series A and Series B Convertible Preferred Stock, returning them to undesignated preferred stock status. These shares were previously cancelled or converted.

  • Annual Meeting Results Confirmed

    The 8-K reports the final voting results from the Annual Meeting on May 19, 2026, confirming the approval of the authorized share increase and other routine proposals.


auto_awesomeAnalysis

Curis Inc. stockholders have formally approved a significant increase in authorized common stock, effectively doubling the number of shares the company can issue. This action, previously proposed in proxy filings, is critical for a company facing a Nasdaq delisting notice and explicitly stating 'going concern' doubt. The authorization provides the company with the necessary headroom to raise substantial capital, likely through highly dilutive offerings, to fund operations and address its precarious financial position. This move confirms the company's strategy to secure its short-term survival at the cost of significant shareholder dilution.

At the time of this filing, CRIS was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $0.46 to $3.13. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CRIS - Latest Insights

CRIS
May 22, 2026, 5:05 PM EDT
Filing Type: PRE 14A
Importance Score:
9
CRIS
May 22, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
CRIS
May 13, 2026, 9:20 AM EDT
Filing Type: 10-Q
Importance Score:
9
CRIS
May 12, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
CRIS
May 12, 2026, 4:00 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
CRIS
May 01, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
9
CRIS
May 01, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
CRIS
Apr 21, 2026, 4:52 PM EDT
Filing Type: DEF 14A
Importance Score:
9
CRIS
Apr 10, 2026, 4:19 PM EDT
Filing Type: PRE 14A
Importance Score:
9
CRIS
Mar 24, 2026, 5:05 PM EDT
Source: Wiseek News
Importance Score:
9